{"id":"dalpiciclib-endocrine-therapy","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"5-20%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4802161","moleculeType":"Small molecule","molecularWeight":"446.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting CDK4/6, dalpiciclib prevents the phosphorylation and activation of the retinoblastoma protein, leading to cell cycle arrest and apoptosis in cancer cells. This mechanism is particularly effective in combination with endocrine therapy, which targets hormone receptors in breast cancer cells.","oneSentence":"Dalpiciclib is a CDK4/6 inhibitor that works by blocking the activity of CDK4/6 enzymes, which are involved in cell cycle progression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:31.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer, hormone receptor-positive and HER2-negative"}]},"trialDetails":[{"nctId":"NCT07354022","phase":"PHASE3","title":"A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-04","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":912},{"nctId":"NCT06650748","phase":"PHASE2","title":"Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Peking University","startDate":"2025-05-01","conditions":"Breast Cancer, Early-stage Breast Cancer","enrollment":100},{"nctId":"NCT07467330","phase":"PHASE3","title":"Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-11-15","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT07432178","phase":"PHASE3","title":"CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-23","conditions":"Breast Cancer","enrollment":2288},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT06107673","phase":"PHASE2","title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-09-30","conditions":"Breast Cancer","enrollment":144},{"nctId":"NCT07189884","phase":"PHASE1, PHASE2","title":"Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-09-23","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":33},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT06599216","phase":"PHASE2","title":"Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-10-08","conditions":"Breast Cancer, HR+/HER2- Breast Cancer","enrollment":30},{"nctId":"NCT06556862","phase":"PHASE2","title":"Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-10-01","conditions":"HR+/HER2- Advanced Breast Cancer","enrollment":155},{"nctId":"NCT07101159","phase":"PHASE2","title":"Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09","conditions":"Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT07005557","phase":"PHASE3","title":"Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1244},{"nctId":"NCT05463601","phase":"PHASE2","title":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08-01","conditions":"Metastatic Breast Cancer","enrollment":132},{"nctId":"NCT06810492","phase":"NA","title":"The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment","status":"NOT_YET_RECRUITING","sponsor":"Hongmei Zheng, PhD","startDate":"2025-04-01","conditions":"Breast Cancer Stage III, Breast Cancer Stage II","enrollment":40},{"nctId":"NCT06344780","phase":"","title":"Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-05-20","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT05176080","phase":"PHASE1, PHASE2","title":"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer","status":"TERMINATED","sponsor":"Henan Cancer Hospital","startDate":"2021-12-08","conditions":"Metastatic Breast Cancer","enrollment":46},{"nctId":"NCT06711094","phase":"NA","title":"Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-01-01","conditions":"HR+/HER2- Advanced Breast Cancer","enrollment":52},{"nctId":"NCT06612814","phase":"PHASE3","title":"PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhimin Shao","startDate":"2024-09-01","conditions":"Breast Cancer Metastatic","enrollment":307},{"nctId":"NCT06176534","phase":"PHASE2","title":"Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-01-01","conditions":"Advanced Breast Cancer, Treatment, HR Low/HER2 Negative","enrollment":240},{"nctId":"NCT06447623","phase":"PHASE3","title":"Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-02-01","conditions":"Advanced Breast Cancer, HR+/HER2- Breast Cancer","enrollment":184},{"nctId":"NCT06149130","phase":"PHASE2","title":"Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-01-11","conditions":"Breast Cancer","enrollment":82},{"nctId":"NCT06341894","phase":"PHASE2","title":"Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-11-17","conditions":"Early Breast Cancer","enrollment":1163},{"nctId":"NCT05861830","phase":"PHASE3","title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05-15","conditions":"Advanced Breast Cancer","enrollment":80},{"nctId":"NCT05949541","phase":"PHASE2","title":"Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-07-26","conditions":"Breast Cancer, Advanced Breast Cancer","enrollment":265},{"nctId":"NCT05759546","phase":"PHASE2","title":"PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-02-01","conditions":"Breast Cancer Metastatic","enrollment":200},{"nctId":"NCT05759572","phase":"PHASE2","title":"Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-02-01","conditions":"Breast Cancer Metastatic","enrollment":145},{"nctId":"NCT05640778","phase":"PHASE2","title":"Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Luminal B/HER2-negative Breast Cancer","enrollment":30},{"nctId":"NCT03772353","phase":"PHASE1, PHASE2","title":"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-05-12","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT05577442","phase":"PHASE2","title":"Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2022-10-20","conditions":"Breast Neoplasm Female","enrollment":52},{"nctId":"NCT05577923","phase":"PHASE2","title":"Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Metastatic Breast Cancer","enrollment":126},{"nctId":"NCT05512416","phase":"PHASE2","title":"Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-08","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT05431504","phase":"PHASE2","title":"The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-06","conditions":"Advanced Breast Cancer","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"dalpiciclib + endocrine therapy","genericName":"dalpiciclib + endocrine therapy","companyName":"Fujian Cancer Hospital","companyId":"fujian-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dalpiciclib is a CDK4/6 inhibitor that works by blocking the activity of CDK4/6 enzymes, which are involved in cell cycle progression. Used for Metastatic breast cancer, hormone receptor-positive and HER2-negative.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}